NICE (UK National Institute for Clinical Excellence): troponin test delays prompt PCI (percutaneous coronary intervention) policy review
This article was originally published in Clinica
Executive Summary
Delays in providing the results of cardiac troponin tests for patients being considered for percutaneous coronary intervention (PCI) has prompted the UK's National Institute for Clinical Excellence (NICE) to review its guidance on the use of drugs to reduce the risk of adverse cardiac events. The decision comes as the institute's Scottish counterpart - the Health Technology Board for Scotland - has begun to appraise troponin testing, with particular emphasis on point-of-care testing as a potential alternative (see page 5).
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.